logo-loader
viewNetscientific PLC

Netscientific hails Wanda’s new medical director

Netscientific hailed the appointment of a renowned cardiologist as medical director at its portfolio firm Wanda.

heart image
A image showing the human heart

Shares in AIM- listed biomedical firm Netscientific PLC (LON:NSCI) ticked higher as it hailed the appointment of a renowned cardiologist as medical director at its California- based portfolio firm Wanda.

She is Dr Suzanne Steinbaum, a board-certified cardiologist and well-known national advocate for women's heart health, the group said.

Wanda is a digital analytics software group, whose aim is to reduce US hospital admissions.

It has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions.

Dr Steinbaum said: "Wanda is at the forefront of a critical turning point in healthcare, in which patient engagement is essential to successful outcomes.

"I have devoted my entire career to the treatment of heart disease through early detection, education, and prevention."

She added :"While heart disease is 80 to 90% preventable, lifestyle changes are critical, and this is where Wanda comes in."

François R. Martelet, chief executive at NetScientific said: "Dr Steinbaum's extensive clinical experience and background in cardiology will make her a valuable addition to Wanda's already distinguished team."

Shares in NetScientific added 0.67% to stand at 75.5p a pop.

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read